Alnylam Pharmaceuticals (NASDAQ:ALNY) released its earnings results on Thursday. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10), Bloomberg Earnings reports. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $37.90 million during the quarter, compared to the consensus estimate of $19.31 million. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. The firm’s revenue for the quarter was up 116.6% compared to the same quarter last year.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $116.32 on Friday. Alnylam Pharmaceuticals has a 1 year low of $44.50 and a 1 year high of $147.63. The company has a market cap of $12,005.21, a P/E ratio of -22.16 and a beta of 2.69. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.
In related news, SVP Laurie Keating sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the transaction, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at $5,639,435. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Maraganore sold 73,415 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total transaction of $9,610,023.50. Following the transaction, the chief executive officer now directly owns 223,125 shares in the company, valued at $29,207,062.50. The disclosure for this sale can be found here. Insiders have sold 220,409 shares of company stock worth $28,667,017 over the last ninety days. 4.30% of the stock is currently owned by insiders.
A number of analysts recently commented on ALNY shares. FBR & Co started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, October 30th. They issued a “buy” rating and a $150.00 target price on the stock. B. Riley started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, November 1st. They issued a “buy” rating and a $240.00 target price on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $14.71 target price (down from $188.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, November 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $152.00 target price (up from $125.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Finally, Cowen reiterated an “outperform” rating and issued a $151.00 target price (up from $117.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $123.93.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.